ArticleCancers2026

FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval.

Ugur Ozkerim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.